GHRS$14.85
$15.07
Chart
Performance
Key Stats
AI GHRS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralGH Research PLC (GHRS) shows mixed signals. Its performance metrics indicate strong short-term gains, but fundamental data suggests a company still in early development with a negative EPS and no revenue reported. Technicals are mixed across different timeframes.
Thematic
GHRS operates in the biopharmaceutical sector, focusing on treatments for depression. While the target market is significant, the company is in the clinical stage with no approved products, making its thematic positioning speculative.
Fundamental
GHRS shows significant losses and no reported revenue. While its cash position is reasonable for its stage, the lack of profitability and revenue raises concerns about its long-term viability without further funding or product success.
Technical
The stock has experienced strong short-term performance across various periods, with positive momentum indicated by most technical indicators on shorter timeframes. However, longer-term technicals suggest a consolidation phase.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 70 |
| Market Need & Demand | 80 |
| Competitive Landscape | 40 |
| Regulatory Environment | 30 |
| Company Specific Risks | 40 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 70 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Moving Averages | 80 |
| Support & Resistance | 75 |
| Volume Analysis | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Recent Performance
The stock has shown significant positive performance over multiple periods, with 1M performance at 38.18%, 6M at 89.21%, and YTD at 115.04%.
Positive Cash Position
The company has a substantial cash and cash equivalents balance of $100,791,000 as of Q4 2024, providing financial flexibility.
Bearish Points (7)
Lack of Revenue
The company has zero reported revenue for the periods 2021-2024, raising significant concerns about its business model and ability to generate sales.
Consistent Net Losses
The company has consistently reported significant net losses, with TTM net income at -$31,728,000 and losses in all reported annual periods, indicating a lack of profitability.
Calendar
September 2025
9
Next Earnings Date
H: $-0.16
A: $-0.20
L: $-0.23
Profile
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Seasonals
Price Target
33.14 USD
The 39 analysts offering 1 year price forecasts for GHRS have a max estimate of 40.00 and a min estimate of 25.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
A leading mental health care company specializing in psilocybin therapy for treatment-resistant depression (TRD), a direct competitor and comparable in the novel depression treatment space.
Weight: 97
A global biotechnology company that is a major investor and incubator in the psychedelic and mental health drug development sector, holding stakes in numerous companies, including COMPASS Pathways.
Weight: 95
A clinical-stage psychedelic medicine company developing novel treatments for mental health conditions, directly comparable to GHRS's focus on psychedelic compounds for psychiatric disorders.
Weight: 94
Developing novel psychedelic molecules and delivery systems aimed at treating mental health conditions, including major depressive disorder, making it a direct competitor in the psychedelic drug development space.